
Coeptis Therapeutics Holdings, Inc.
91
Recent developments include the extinguishment of a convertible note strengthening capital structure, filing of a Form S-4 for a merger with Z Squared Inc., and ongoing strategic partnerships and business expansions in AI and technology sectors.
- Coeptis Therapeutics Holdings, Inc. announced extinguishment of a convertible note, strengthening its capital structure in July 2025 [N7].
- The company filed a Form S-4 registration statement for a proposed merger with Z Squared Inc. in June 2025 [N8].
- Coeptis entered a definitive merger agreement with Z Squared Inc. to pursue a crypto asset mining business, completed in April 2026 [N8].
- Recent strategic partnerships include AI-driven marketing solutions and technology hubs in India, as well as licensing agreements for next-generation cell therapy development [N7].
Coeptis Therapeutics Holdings, Inc. underwent a significant business transformation in April 2026, shifting from biopharmaceuticals to crypto asset mining through a merger with Z Squared Inc. The company owns a substantial fleet of ASIC miners and relies exclusively on Minting Dome Inc. for hosting, power, and operational support under a Master Services Agreement that grants Minting Dome broad operational control and limits Coeptis's direct oversight. The company has a new management team with crypto mining experience but limited public company governance experience. Financially, Coeptis reported $1.58 million in revenue and a net loss of $13.79 million for Q2 2026, with strong liquidity metrics. The company has also engaged in strategic transactions and partnerships related to AI and technology integration.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of June 30, 2026, Coeptis Therapeutics Holdings, Inc. operates primarily in crypto asset mining following a merger and business transformation completed in April 2026. The company owns a fleet of approximately 9,800 ASIC miners and conducts mining operations exclusively under a Master Services Agreement with Minting Dome Inc., which controls hosting and operational services. The company reported quarterly revenue of $1.58 million and a net loss of $13.79 million for Q2 2026, with strong liquidity ratios indicating solid short-term financial position [S2].
The company has established a significant crypto mining asset base and secured exclusive operational support through Minting Dome, enabling it to focus on scaling mining operations. Strong liquidity ratios provide financial flexibility to pursue growth opportunities and strategic acquisitions. The management team's crypto mining experience and recent partnerships in AI and technology integration could enhance operational efficiency and open new revenue streams. The extinguishment of convertible notes strengthens the capital structure, potentially improving investor confidence.
The company's reliance on Minting Dome for all hosting and operational services creates a single point of failure risk, with limited ability to control or influence day-to-day operations. The new management team has limited experience managing a public company, which may lead to compliance and reporting challenges. The company reported a significant net loss and has substantial execution and integration risks following its recent merger and business transformation. Pending acquisitions and strategic transactions carry risks of non-completion, dilution, and integration difficulties. Regulatory and reputational risks exist due to historical related-party transactions and ongoing SEC enforcement actions involving former controlling stockholders.
Coeptis's operational model depends heavily on its exclusive Master Services Agreement with Minting Dome Inc., which provides critical infrastructure and operational services for its crypto mining activities. The exclusivity and operational control granted to Minting Dome create a high dependency risk but also a barrier to entry for competitors lacking similar infrastructure partnerships. The company's ownership of a large ASIC miner fleet contributes to its asset base, but the lack of direct operational control over mining facilities limits its operational flexibility. The recent business transformation and new management team position the company in a specialized niche of crypto asset mining with potential strategic partnerships in AI and technology sectors.
• Dependency on Minting Dome Inc.: All mining operations are conducted under an exclusive Master Services Agreement with Minting Dome, which controls operational details and limits Coeptis's oversight. Termination or adverse changes in this relationship could materially impact operations.
• Management and Governance Risks: The new management team has limited experience operating a public company, which may result in internal control weaknesses, compliance failures, and reporting inaccuracies.
• Business Transformation and Integration Risks: The recent merger and spin-out significantly changed the company's business, assets, and management, creating risks of unknown liabilities, regulatory challenges, and operational disruptions.
• Financial Performance and Going Concern: The company reported a net loss of $13.79 million for Q2 2026 and has a history of substantial doubt about its ability to continue as a going concern, dependent on achieving profitability and accessing capital markets.
• Acquisition and Strategic Transaction Risks: Pending acquisitions such as Paradox Data, LLC, and others carry risks of non-completion, dilution, and failure to achieve anticipated benefits.
• Related-Party and Reputational Risks: Historical relationships with entities involved in SEC enforcement proceedings and related-party transactions may expose the company to reputational harm and regulatory scrutiny.
Business trends: Transitioned from biopharmaceuticals to crypto asset mining with strategic partnerships in AI and technology sectors.
Execution milestones: Completion of merger with Z Squared, integration of new management, and pursuit of acquisitions such as Paradox Data, LLC.
Key risks: High dependency on Minting Dome for operations, management's limited public company experience, financial losses, and risks from pending acquisitions and regulatory scrutiny.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Coeptis Therapeutics Holdings, Inc. completed a merger on April 24, 2026, changing its principal business from biopharmaceuticals to crypto asset mining through Z Squared and its subsidiaries [S1].
- The company owns approximately 9,800 ASIC miners contributed by BSG Series CM, LLC as its primary operating assets [S1].
- All crypto asset mining operations are conducted under a Master Services Agreement (MSA) with Minting Dome Inc., which provides hosting, power, infrastructure, and operational support, retaining substantial operational control [S1].
- The MSA restricts Coeptis's ability to supervise or control day-to-day mining operations and limits physical access to mining hardware [S1].
- The MSA has an initial term of three years with no automatic renewal and exclusivity provisions, creating a single point of failure risk if Minting Dome ceases to provide services [S1].
- The company has a new management team primarily from Z Squared with experience in crypto mining but limited public company experience [S1].
- The company spun out its legacy biopharmaceutical assets except for a continuing interest in GEAR Therapeutics, Inc. [S1].
- Financial snapshot as of June 30, 2026, shows cash and equivalents of $15.49 million, current assets of $15.53 million, current liabilities of $2.03 million, and revenue of $1.58 million for the quarter [S2].
- Net loss for the quarter ended June 30, 2026, was $13.79 million with basic and diluted EPS of -$0.28 [S2].
- Liquidity ratios as of June 30, 2026, include a current ratio of 7.66 and a cash ratio of 7.67, indicating strong short-term liquidity [S2].
- The company announced the extinguishment of a convertible note, strengthening its capital structure in July 2025 [N7].
- Coeptis filed a Form S-4 registration statement for a proposed merger with Z Squared Inc. in June 2025 [N8].
- The company entered a definitive merger agreement with Z Squared Inc. to pursue a crypto asset mining business, completed in April 2026 [N8].
- Recent news includes strategic partnerships and business developments related to AI, technology hubs, and licensing agreements in 2025 [N7,N8].
Generated 2026-08-17
- S1 | 2026-03-19 | 10-K
- S2 | 2026-08-13 | 10-Q
- N1 | 2026-08-17 | www.nasdaq.com | Amazon's Stake in Anthropic Is Now Big Enough to Move Its Earnings. Here's How That Compares to Alphabet's Stake in SpaceX. | https://www.nasdaq.com/articles/amazons-stake-anthropic-now-big-enough-move-its-earnings-heres-how-compares-alphabets
- N2 | 2026-05-19 | www.nasdaq.com | Stocks Settle Mixed as Iran War Remains Unresolved | https://www.nasdaq.com/articles/stocks-settle-mixed-iran-war-remains-unresolved
- N3 | 2026-05-19 | www.nasdaq.com | Bank Leumi Q1 Earnings Fall | https://www.nasdaq.com/articles/bank-leumi-q1-earnings-fall
- N4 | 2026-05-19 | www.nasdaq.com | Wheat Rally Pushing Higher on US/China Fact Sheet Trade Numbers | https://www.nasdaq.com/articles/wheat-rally-pushing-higher-us-china-fact-sheet-trade-numbers
- N5 | 2026-05-19 | www.nasdaq.com | Gossamer Bio Q1 Net Loss Expands; Eyes On The Pre-NDA Meeting With FDA For Seralutinib W In Mid-June | https://www.nasdaq.com/articles/gossamer-bio-q1-net-loss-expands-eyes-pre-nda-meeting-fda-seralutinib-w-mid-june
- N6 | 2026-05-19 | www.nasdaq.com | Allegiant Air Announces Eight New Non-Stop Routes To Florida | https://www.nasdaq.com/articles/allegiant-air-announces-eight-new-non-stop-routes-florida
- N7 | 2025-07-22 | www.nasdaq.com | Coeptis Therapeutics Holdings, Inc. Announces Extinguishment of Convertible Note, Strengthening Capital Structure | https://www.nasdaq.com/articles/coeptis-therapeutics-holdings-inc-announces-extinguishment-convertible-note-strengthening
- N8 | 2025-06-26 | www.nasdaq.com | Coeptis Therapeutics Files Form S-4 Registration Statement for Proposed Merger with Z Squared Inc. | https://www.nasdaq.com/articles/coeptis-therapeutics-files-form-s-4-registration-statement-proposed-merger-z-squared-inc
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


